NEWTOWN, PA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced that it has repurchased an aggregate of 1,604,676 shares of Forian common stock in a privately negotiated transaction at redemption price of $2.15 per share for an aggregate purchase price of approximately $3.45 million. The redeemed shares were cancelled and retired and returned to authorized and unissued shares.
About Forian
Forian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. For more information, please visit the Company’s website at www.forian.com.
Media and Investor Contact:
forian.com/investors
This email address is being protected from spambots. You need JavaScript enabled to view it.
267-225-6263
| Last Trade: | US$1.97 |
| Daily Change: | 0.05 2.60 |
| Daily Volume: | 4,886 |
| Market Cap: | US$61.290M |
November 13, 2024 August 14, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
